Takeda continues to explore innovative medicines in Shanghai
Last year, Takeda established its Chinese headquarters and development center in Shanghai. It aimed to make the Chinese market the company's second largest market in the world by 2030.
As one of the important engines of Takeda's global research and development (R&D) centers, the Takeda Asia Development Center was established in Shanghai in 2012, and specializes in the development of innovative drugs.
The company's Shanghai headquarters is based on three principles: the promotion of clinical research strength, the incorporation of China into its global R&D program plan and the exploration of external innovation.
Since 2015, Takeda has allocated special funds for five consecutive years to support the development of new drugs in China and has benefited Chinese citizens in a faster and more effective way.
Brigatinib Tablets, a medicine used to treat lung cancer was released last month. It serves as a powerful weapon for precisely treating lung cancer, and the company plans to release a series of innovative medicines in the future.
Takeda believes that the industrial agglomeration effect will boost the development and upgrading of Shanghai's biopharmaceutical industry.
Researchers work in a laboratory of Takeda to develop new medicines. [Photo/WeChat account: pdnews]